1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
(
- Contribution to journal › Article
- 2021
-
Mark
Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis : results from the randomised controlled SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
(
- Contribution to journal › Article
- 2020
-
Mark
Abatacept in rheumatoid arthritis : Survival on drug, clinical outcomes, and their predictors - Data from a large national quality register
(
- Contribution to journal › Article
- 2019
-
Mark
Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis : Results from the SWEFOT trial
(
- Contribution to journal › Article
- 2017
-
Mark
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
(
- Contribution to journal › Article
-
Mark
A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus
(
- Contribution to journal › Article
- 2016
-
Mark
Correlates of leisure time physical inactivity in a scandinavian population : A basis for interventions
(
- Contribution to journal › Article
-
Mark
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article